ACCELERATED PUBLICATION
Biochemical Analysis of Transcriptional Repression by Drosophila Histone Deacetylase 1*

Xuejun HuangDagger and James T. Kadonaga§

From the Section of Molecular Biology, 0347, and Center for Molecular Genetics, University of California, San Diego, La Jolla, California 92093-0347

Received for publication, January 23, 2001, and in revised form, March 6, 2001



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

To study the mechanisms by which deacetylases regulate transcription by RNA polymerase II, we investigated the biochemical properties of purified recombinant Drosophila histone deacetylase 1 (dHDAC1, also known as dRPD3). We found that purified dHDAC1 and Gal4-dHDAC1 polypeptides possess substantial deacetylase activity. Thus, deacetylation by dHDAC1 does not require any additional cofactors. Gal4-dHDAC1, but not dHDAC1, was observed to repress transcription in vitro by about 2-3-fold from chromatin templates, but not from naked DNA templates, in a Gal4 site-dependent manner. This magnitude of repression is similar to that commonly seen by deacetylases in vivo, as assessed by treatment of cells with deacetylase inhibitors. Transcriptional repression by Gal4-dHDAC1 was blocked by the deacetylase inhibitor, FR901228, and thus, deacetylase activity correlates with repression. Single round transcription analyses showed that Gal4-dHDAC1 reduces the absolute number of productive initiation complexes with chromatin templates. Moreover, with chromatin templates that were assembled with completely purified components, Gal4-dHDAC1 was found to deacetylate nucleosomal histones as well as to repress transcription. These experiments provide biochemical evidence for the requirement of chromatin for transcriptional repression by dHDAC1 and further show that dHDAC1 acts to repress the transcription initiation process.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The precise control of gene transcription is essential for the proper growth and development of an organism. In eukaryotes, there are thousands of proteins that participate in the regulation of transcription by RNA polymerase II. These factors include sequence-specific DNA-binding proteins that interact with enhancer and silencer elements, the RNA polymerase II transcriptional machinery, chromatin remodeling factors, and enzymes that covalently modify histones and other proteins such as transcription factors (for reviews, see Refs. 1-14).

There has recently been considerable effort devoted to the effects of histone acetyltransferases (HATs)1 as well as histone deacetylases (HDACs) upon transcriptional activity. In general, the acetylation of core histones correlates with transcriptional activation, whereas the deacetylation of core histones correlates with transcriptional repression. The importance of HATs and HDACs in the control of gene expression is well established, but the basic molecular mechanisms by which they act are a subject of current investigation. For instance, HATs can acetylate a variety of proteins other than core histones, and thus, it will be important to determine the importance of the acetylation of histones as well as nonhistone proteins.

Transcriptional studies of HDACs have been generally carried out in transiently transfected cells. In many instances, the treatment of cells with HDAC inhibitors, such as TSA or trapoxin, has been found to result in a 2-4-fold increase in the transcription of HDAC-repressed genes (15-20), although in some cases, higher levels of transcriptional enhancement by HDAC inhibitors have been observed (21-23). LexA- or Gal4-HDAC fusion proteins have also been found to repress transcription in vivo (24-26), but the role of deacetylation in repression by these factors was not tested with HDAC inhibitors.

The ability of HDACs to repress transcription in vitro has not yet been tested. Hence, it is not yet known whether a chromatin template is required for repression by HDACs. It is possible, for instance, that HDACs repress transcription by acting through transcription factors or coregulators instead of the chromatin template. It is also not known whether HDACs repress the assembly of the transcription preinitiation complex or a post-initiation process such as transcriptional elongation.

To address these questions, we performed a biochemical analysis of Drosophila histone deacetylase 1 (dHDAC1, also known as dRPD3; Refs. 27 and 28). To this end, we prepared purified, recombinant dHDAC1 proteins that are highly active for the deacetylation of histones in vitro and then investigated the ability of these proteins to repress transcription by RNA polymerase II in vitro.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Transcription Factors and DNA Templates-- His6-tagged NF-kappa B p65 protein (29) was synthesized in Sf9 cells by using a recombinant baculovirus kindly provided by Dr. J. Hiscott (Lady Davis Institute, Montreal, Canada). The p65 protein was synthesized and purified essentially as described for His6-tagged p300 (30, 31). FLAG-tagged Sp1 was purified by using a recombinant baculovirus that was kindly provided by Drs. Soojin Ryu and Robert Tjian (University of California, Berkeley, CA). Constructions that encode His6-tagged versions of full-length dHDAC1 and Gal4-dHDAC1 were prepared from the dHDAC1 cDNA (27) that was generously provided by Drs. Andrew Barlow and Bryan Turner (University of Birmingham, United Kingdom). The resulting dHDAC1 and Gal4-dHDAC1 proteins were synthesized in Sf9 cells by using a baculovirus expression system (PharMingen) and purified by Ni(II) affinity chromatography (Ni-NTA resin; Qiagen). Gal4-dHDAC1 consists of the N-terminal 147 amino acid residues of the yeast Gal4 protein (which contains the DNA binding region) fused to the N terminus of full-length dHDAC1 protein. The plasmid pHIV contains the proximal promoter region of the HIV-1 long terminal repeat (from -137 to +38 relative to the +1 transcriptional start site). The plasmid pG5HIV is identical to pHIV except that it contains five tandem Gal4 binding sites (derived from pGIE-0; Ref. 32) upstream of the HIV-1 promoter, with the nearest Gal4 site located 48 base pairs from the upstream NF-kappa B site in the HIV-1 promoter.

Histone Deacetylase Assays-- Histone deacetylase assays with free histones (as in Fig. 1) were performed as follows. Purified Drosophila core histones were prepared by the method of Bulger and Kadonaga (33) and then acetylated with [1-14C]acetic anhydride (ICN Radiochemicals), as described by Hebbes et al. (34). The resulting 14C-acetyl histones were separated from the free labeled acetate and unreacted acetic anhydride by extensive dialysis. Histone deacetylase reactions were performed by incubation of the purified dHDAC derivatives (200 nM dHDAC1 or Gal4-dHDAC1) with 14C-acetyl histones (20 µg/ml; 1.5 µM in histone polypeptides) for 30 min at 30 °C in buffer (50 µl of total reaction volume) consisting of 50 mM Hepes, K+, pH 7.6, 50 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, and 5% glycerol. The reactions were terminated by the addition of HCl (to 0.82 M final concentration) and acetic acid (to 0.12 M final concentration), and the resulting 14C-labeled acetic acid was extracted with ethyl acetate and quantitated with a liquid scintillation counter. The reported amounts of free 14C-acetic acid were obtained by subtracting the background levels of 14C-acetic acid (in reactions with buffer only) from the amounts of 14C-acetic acid observed with dHDAC1 or Gal4-dHDAC1. (The background levels of 14C-acetic acid were typically about 13-20% of the total radiolabeled material.)

The deacetylation of nucleosomal histones (as in Fig. 4A) was assayed as follows. Purified Drosophila core histones (1 mg/ml; Ref. 33) were acetylated with purified His6-tagged human p300 (100 nM; Refs. 30 and 31) and 1 mM acetyl-CoA for 30 min at 30 °C. The His6-tagged p300 was depleted from the sample with Ni-NTA resin (Qiagen), and the resulting p300-acetylated histones were assembled into chromatin with purified ACF and dNAP-1, as described by Ito et al. (35). This chromatin was incubated with purified dHDAC1 derivatives (100 nM Gal4-dHDAC1 or dHDAC1) for 30 min at 30 °C, digested with micrococcal nuclease, and immunoprecipitated with anti-acetyl (Lys9, Lys14) histone H3 or anti-acetyl (Lys5, Lys8, Lys12, Lys16) histone H4 (Upstate Biotechnology). The resulting DNA fragments were resolved by 1.25% agarose gel electrophoresis and detected by Southern blot analysis.

The HDAC inhibitor FR901228 (36, 37) was a generous gift of Dr. Hidenori Nakajima (Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan). Prior to use, FR901228 was dissolved in methanol to a concentration of 0.5 mg/ml and then further diluted to a working stock solution of 0.1 mg/ml in methanol and stored at -20 °C. The HDAC inhibitor TSA (Sigma catalog number T8552; Refs. 38 and 39) was dissolved in ethanol to a concentration of 1.5 mg/ml and then further diluted to a working stock solution of 0.15 mg/ml in ethanol and stored at -20 °C. The addition of FR901228 or TSA resulted in a final concentration of 0.1% (v/v) methanol or ethanol in the histone deacetylase or transcription reactions. Control reactions with buffers containing 0.1% methanol or ethanol were performed to ensure that the effects seen with FR901228 or TSA were due to the specific inhibitors instead of the buffer medium.

Chromatin Assembly and in Vitro Transcription-- Transcription of S190-assembled chromatin (33, 40) was performed with HeLa nuclear extracts, essentially as described previously (30, 31), except that a 3-fold mass excess (relative to the template DNA prior to chromatin assembly) of pUC118 was added to the reaction medium after chromatin assembly to remove any additional core histones. Transcription of chromatin that was assembled with purified recombinant ACF, purified recombinant dNAP-1, purified core histones, DNA, and ATP was carried out as described by Jiang et al. (41), except that the core histones were pre-acetylated with purified recombinant p300 and acetyl CoA, as described above for the nucleosomal histone deacetylase assays. Quantitation of the data was carried out with a PhosphorImager (Molecular Dynamics). All reaction conditions were performed in duplicate, and each experiment was performed a minimum of two (but typically, several) independent times to establish the reproducibility of the results. The amounts of transcription are reported as the mean ± S.D., relative to a reference indicated by parentheses.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

To study the mechanisms by which histone deacetylases regulate transcription by RNA polymerase II, we synthesized Drosophila HDAC1 (dHDAC1) and Gal4-dHDAC1 in Sf9 cells by using a baculovirus expression system and then purified the proteins to near homogeneity (Fig. 1A). dHDAC1 is in the Rpd3-like family of histone deacetylases and is also known as dRPD3 (27, 28). Gal4-dHDAC1 consists of the Gal4 DNA-binding domain fused to the N terminus of full-length dHDAC1.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Purified recombinant dHDAC1 and Gal4-dHDAC1 possess high levels of histone deacetylase activity. A, purification of dHDAC1 and Gal4-dHDAC1. His6-tagged versions of full-length dHDAC1 and Gal4-dHDAC1 were synthesized in Sf9 cells with a baculovirus expression system and then purified to near homogeneity by Ni(II) affinity chromatography. The purified proteins were subjected to 10% polyacrylamide-SDS gel electrophoresis and staining with Coomassie Brilliant Blue R-250. The positions of molecular mass markers (in kilodaltons) are indicated. B, histone deacetylase activity of purified dHDAC1 and Gal4-dHDAC1. Where indicated, reactions were performed in the presence of the following histone deacetylase inhibitors: sodium butyrate (10 mM), FR901228 (100 ng/ml; 185 nM), or TSA (150 ng/ml; 500 nM).

The purified recombinant dHDAC1 and Gal4-dHDAC1 were then tested for histone deacetylase activity. For these assays, we prepared 14C-acetyl histones by incubation of purified Drosophila core histones (which are mostly unacetylated) with [1-14C]acetic anhydride under conditions that result in the acetylation of essentially all of the unmodified lysine residues in the core histones (34). With these 14C-acetyl histones, we observed that purified dHDAC1 and Gal4-dHDAC1 can deacetylate about 38 and 15%, respectively, of the total acetyl lysine residues at a molar ratio of histone polypeptides to dHDAC1 (or Gal4-dHDAC1) of ~7.5:1 (Fig. 1B). These findings thus indicate that the purified dHDAC1 protein is highly active for deacetylation of free histones in the absence of any other cofactors.

We also observed that the HDAC activity of the recombinant proteins is completely inhibited by 10 mM sodium butyrate, 150 ng/ml (500 nM) TSA, or 100 ng/ml (185 nM) FR901228 (Fig. 1B). Whereas sodium butyrate and TSA are well known HDAC inhibitors, FR901228 has recently been found to be a potent and specific inhibitor of histone deacetylases (36, 37). In fact, FR901228 inhibits HDAC activity at a lower concentration than TSA (37). Therefore, based on the potency, specificity, and chemical stability of FR901228, we chose to use this compound for the inhibition of HDAC activity.

Next, we tested the ability of the dHDAC1 proteins to modulate transcription by RNA polymerase II. To this end, we used a chromatin transcription system based on the Drosophila S190 chromatin assembly extract (30-32, 40, 42). Two different plasmids were used as reporter templates: pHIV, which contains the HIV-1 long terminal repeat promoter; and pG5HIV, which is identical to pHIV except that it contains five Gal4 binding sites upstream of the HIV promoter fragment (Fig. 2). (To minimize steric effects of the binding of Gal4-dHDAC1 to the promoter, the Gal4 sites were placed upstream of the HIV-1 promoter.) The plasmids were assembled into chromatin with the S190 extract and then subjected to in vitro transcription analysis with a HeLa nuclear extract. Transcription was activated by Sp1 and NF-kappa B p65 proteins, which were added along with the dHDAC1 derivatives subsequent to chromatin assembly. As shown in Fig. 2, Gal4-dHDAC1, but not dHDAC1, represses transcription by about 2-fold from pG5HIV, but not from pHIV. Thus, transcriptional repression by dHDAC1 requires its recruitment to the template, which occurs, in this instance, via the Gal4 protein fusion and Gal4 binding sites. It is additionally important to note that dHDAC1 was found to have higher HDAC activity than Gal4-dHDAC1 (Fig. 1B), and hence, the inability of dHDAC1 to repress transcription was not due to the lack of intrinsic HDAC activity.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   Gal4-dHDAC1, but not dHDAC1, represses transcription in vitro with chromatin templates. Chromatin was assembled onto template DNAs containing either five (pG5HIV) or zero (pHIV) Gal4 sites located upstream of the promoter region of the HIV-1 long terminal repeat. Where indicated, purified dHDAC1 (100 nM), Gal4-dHDAC1 (100 nM), Sp1 (10 nM), and NF-kappa B p65 (100 nM) were added to the chromatin templates, and transcription was carried out with a HeLa nuclear extract. The resulting transcripts were detected by primer extension analysis, and the reverse transcription products are shown. Transcriptional activity is reported as relative to that observed with Sp1 and NF-kappa B p65 in the absence of any dHDAC derivative, which is designated as "(100)".

We further examined the repression of transcription by the Gal4-dHDAC1 protein as follows. First, we found that repression is blocked by the HDAC inhibitor, FR901228, and that repression is not observed with Gal4-(1-147) alone (which corresponds to the Gal4 portion of Gal4-dHDAC1) (Fig. 3A). Thus, repression requires the dHDAC1 protein and correlates with the deacetylase activity. Second, we observed that Gal4- dHDAC1 does not repress transcription from naked DNA templates (Fig. 3B). Hence, repression by Gal4-dHDAC1 requires chromatin and is not due to an effect upon the intrinsic transcription process.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 3.   Biochemical characterization of transcriptional repression by Gal4-dHDAC1. A, the deacetylase inhibitor, FR901228, blocks transcriptional repression by Gal4-dHDAC1. Chromatin transcription reactions were performed with pG5HIV, as in Fig. 2, in the presence of 100 nM Gal4-dHDAC1 or Gal4-(1-147) (which corresponds to the Gal4 portion of Gal4-dHDAC1), as indicated. Where noted, FR901228 (100 ng/ml) was added to the reaction medium at the same time as the Gal4-dHDAC1 protein. B, Gal4-dHDAC1 does not repress transcription from naked DNA templates. Transcription reactions were performed as in Fig. 2, except that chromatin was initially assembled onto a 3-fold mass excess of pUC118 (relative to standard conditions with pG5HIV) and then pG5HIV template DNA was added to the reaction medium after chromatin assembly was complete. C, Gal4-dHDAC1 reduces the efficiency of formation of productive transcription preinitiation complexes. Single round chromatin transcription reactions were performed by the addition of 0.2% (w/v) Sarkosyl after transcription initiation.

To determine the step in the transcription process that is affected by Gal4-dHDAC1, we carried out single round transcription reactions. In these experiments, we used the detergent Sarkosyl, which inhibits the assembly of the transcription preinitiation complex but not the elongation of the transcriptionally engaged polymerase (43-45). Chromatin transcription reactions were performed as described in the legend to Fig. 2 and then Sarkosyl was added immediately (10 s) after the initiation of transcription by the addition of ribonucleoside 5'-triphosphates. These experiments revealed that Gal4-dHDAC1 mediates about 3.5-fold repression of the assembly of productive transcription preinitiation complexes (Fig. 3C). Moreover, repression by Gal4-dHDAC1 was found to be inhibited by FR901228 as well as dependent upon the presence of Gal4 sites in the DNA template. Therefore, these results indicate that Gal4-dHDAC1 represses the transcription initiation process.

To investigate further the requirement for chromatin for repression by Gal4-dHDAC1, we tested the effect of Gal4- dHDAC1 upon chromatin templates that were assembled with completely purified components instead of the crude S190 extract. In these experiments, periodic nucleosome arrays were assembled with purified recombinant ACF, purified recombinant dNAP-1, purified core histones, plasmid DNA (pG5HIV or pHIV), and ATP, as described previously by Ito et al. (35). The chromatin that is assembled with the purified factors is not subject to potential alteration by undefined factors that are present in the S190 extract.

We first tested the ability of dHDAC1 and Gal4-dHDAC1 to deacetylate histones that are packaged into chromatin. With chromatin containing five Gal4 sites, Gal4-dHDAC1 deacetylates nucleosomal histones H3 and H4 more efficiently than dHDAC1 (Fig. 4A). This preferential deacetylation by Gal4-dHDAC1 relative to dHDAC1 was not seen with a template (pHIV) lacking Gal4 sites (data not shown). In addition, the deacetylation of nucleosomal H3 and H4 was inhibited by FR901228 (Fig. 4A). We thus conclude that Gal4-dHDAC1 can deacetylate nucleosomal histones when the protein is recruited to the chromatin template.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 4.   Gal4-dHDAC1 represses transcription from chromatin templates that are assembled with completely purified components. A, deacetylation of nucleosomal histones by Gal4-dHDAC1. Chromatin was assembled with p300-acetylated histones and purified assembly factors (ACF and dNAP-1) and then incubated with dHDAC1 derivatives (100 nM Gal4-dHDAC1 or dHDAC1). Where noted, FR901228 (200 ng/ml) was included to inhibit HDAC activity. The samples were digested with micrococcal nuclease and then immunoprecipitated with anti-acetyl (Lys9, Lys14) histone H3 or anti-acetyl (Lys5, Lys8, Lys12, and Lys16) histone H4 (Upstate Biotechnology). The resulting DNA fragments were resolved by 1.25% agarose gel electrophoresis and detected by Southern blot analysis. B, transcription of chromatin that is assembled with purified components. Chromatin was assembled onto either pG5HIV (five Gal4 sites) or pHIV (zero Gal4 sites) with purified ACF and dNAP-1. Gal4-dHDAC1 (100 nM) was added after chromatin assembly. Where noted, FR901228 (100 ng/ml) was added at the same time as Gal4-dHDAC1. Transcription was carried out with a HeLa nuclear extract supplemented with 15 µM acetyl-CoA, as described by Jiang et al. (41).

Next, we examined the effects of Gal4-dHDAC1 upon transcription of chromatin that is assembled with the purified components. Chromatin was assembled onto pG5HIV (five Gal4 sites) or pHIV (no Gal4 sites), as described above for the chromatin deacetylase assays (Fig. 4A) and then transcribed with a HeLa extract. In these experiments, we observed that Gal4-dHDAC1 mediates a 2.5-fold repression that is dependent upon Gal4 binding sites and is inhibited by FR901228 (Fig. 4B). Thus, these results with the defined chromatin templates further support the conclusion that chromatin is required for repression by Gal4-dHDAC1.

In summary, we have found that purified recombinant dHDAC1 and Gal4-dHDAC1 proteins are highly active histone deacetylases in the absence of any other factors and that Gal4-dHDAC1 is able to repress transcription in vitro in a chromatin-specific manner. Transcriptional repression by Gal4-dHDAC1 is blocked by the deacetylase inhibitor, FR901228. With chromatin templates, we observed a 2-3-fold repression of transcription by Gal4-dHDAC1. Consistent with our results, many studies carried out in vivo have found that TSA or trapoxin treatment of cells causes a 2-4-fold increase in transcription (15-20, 24). The collective data suggest that many processes, including protein deacetylation, contribute to the proper regulation of gene activity.

The findings of this study provide biochemical evidence for the requirement of chromatin for transcriptional repression by HDACs and further reveal that HDACs repress transcription initiation. In addition, the availability of highly active, purified recombinant dHDAC1 will facilitate the analysis of the role of protein deacetylation in a variety of cellular processes.

    ACKNOWLEDGEMENTS

We thank Dmitry Fyodorov, Patricia Willy, Vassilios Alexiadis, Buyung Santoso, and Thomas Boulay for critical reading of the manuscript. We are very grateful to Hidenori Nakajima (Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan) for the generous gift of FR901228, Andrew Barlow and Bryan Turner for kindly providing the cDNA for dHDAC1 (also known as dRPD3), Soojin Ryu and Robert Tjian for the FLAG-Sp1 baculovirus, and Michel Weber for suggesting the use of FR901228 as an HDAC inhibitor.

    FOOTNOTES

* This work was supported by Grant GM 46995 from the National Institutes of Health (to J. T. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Fellow of The Leukemia & Lymphoma Society.

§ To whom correspondence should be addressed: Section of Molecular Biology, 0347, Pacific Hall, Rm. 2212B, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0347. Tel.: 858-534-4608; Fax: 858-534-0555; E-mail: jkadonaga@ucsd.edu.

Published, JBC Papers in Press, March 7, 2001, DOI 10.1074/jbc.C100034200

    ABBREVIATIONS

The abbreviations used are: HAT, histone acetyltransferase; HDAC, histone deacetylase; dHDAC1, Drosophila histone deacetylase 1; NF-kappa B, nuclear factor kappa B; p65, NF-kappa B p65 protein; TSA, trichostatin A; HIV, human immunodeficiency virus; Ni-NTA, nickel-nitrilotriacetic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Brown, C. E., Lechner, T., Howe, L., and Workman, J. L. (2000) Trends Biochem. Sci. 25, 15-19[CrossRef][Medline] [Order article via Infotrieve]
2. Cheung, P., Allis, C. D., and Sassone-Corsi, P. (2000) Cell 103, 263-271[Medline] [Order article via Infotrieve]
3. Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev. 14, 121-141[Free Full Text]
4. Grunstein, M. (1997) Nature 389, 349-352[CrossRef][Medline] [Order article via Infotrieve]
5. Kingston, R. E., and Narlikar, G. J. (1999) Genes Dev. 13, 2339-2352[Free Full Text]
6. Kornberg, R. D., and Lorch, Y. (1999) Cell 98, 285-294[Medline] [Order article via Infotrieve]
7. Lemon, B., and Tjian, R. (2000) Genes Dev. 14, 2551-2569[Free Full Text]
8. Orphanides, G., and Reinberg, D. (2000) Nature 407, 471-475[CrossRef][Medline] [Order article via Infotrieve]
9. Pazin, M. J., and Kadonaga, J. T. (1997) Cell 89, 325-328[Medline] [Order article via Infotrieve]
10. Peterson, C. L., and Workman, J. L. (2000) Curr. Opin. Genet. Dev. 10, 187-192[CrossRef][Medline] [Order article via Infotrieve]
11. Strahl, B. D., and Allis, C. D. (2000) Nature 403, 41-45[CrossRef][Medline] [Order article via Infotrieve]
12. Struhl, K. (1999) Cell 98, 1-4[Medline] [Order article via Infotrieve]
13. Turner, B. M. (2000) Bioessays 22, 836-845[CrossRef][Medline] [Order article via Infotrieve]
14. Wolffe, A. P. (1995) Chromatin Structure and Function , 2nd Ed. , Academic Press, London
15. Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 43-48[CrossRef][Medline] [Order article via Infotrieve]
16. Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., and Eisenman, R. N. (1997) Cell 89, 349-356[Medline] [Order article via Infotrieve]
17. Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., and Evans, R. M. (1997) Cell 89, 373-380[Medline] [Order article via Infotrieve]
18. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., Seiser, C., Grignani, F., Lazar, M. A., Minucci, S., and Pelicci, P. G. (1998) Nature 391, 815-818[CrossRef][Medline] [Order article via Infotrieve]
19. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. (1998) Nature 391, 811-814[CrossRef][Medline] [Order article via Infotrieve]
20. Nan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A. (1998) Nature 393, 386-389[CrossRef][Medline] [Order article via Infotrieve]
21. Hassig, C. A., Fleischer, T. C., Billin, A. N., Schreiber, S. L., and Ayer, D. E. (1997) Cell 89, 341-347[Medline] [Order article via Infotrieve]
22. Jones, P. L., Veenstra, G. J. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and Wolffe, A. P. (1998) Nat. Genet. 19, 187-191[CrossRef][Medline] [Order article via Infotrieve]
23. Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Lorain, S., Le Villain, J. P., Troalen, F., Trouche, D., and Harel-Bellan, A. (1998) Nature 391, 601-605[CrossRef][Medline] [Order article via Infotrieve]
24. Kadosh, D., and Struhl, K. (1997) Cell 89, 365-371[Medline] [Order article via Infotrieve]
25. Yang, W.-M., Inouye, C., Zeng, Y., Bearss, D., and Seto, E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12845-12850[Abstract/Free Full Text]
26. Yang, W.-M., Yao, Y.-L., Sun, J.-M., Davie, J. R., and Seto, E. (1997) J. Biol. Chem. 272, 28001-28007[Abstract/Free Full Text]
27. Johnson, C. A., Barlow, A. L., and Turner, B. M. (1998) Gene (Amst.) 221, 127-134[CrossRef][Medline] [Order article via Infotrieve]
28. De Rubertis, F., Kadosh, D., Henchoz, S., Pauli, D., Reuter, G., Struhl, K., and Spierer, P. (1996) Nature 384, 589-591[CrossRef][Medline] [Order article via Infotrieve]
29. Lin, R., Gewert, D., and Hiscott, J. (1995) J. Biol. Chem. 270, 3123-3131[Abstract/Free Full Text]
30. Kraus, W. L., and Kadonaga, J. T. (1998) Genes Dev. 12, 331-342[Abstract/Free Full Text]
31. Kraus, W. L., and Kadonaga, J. T. (1999) in Nuclear Receptors: A Practical Approach (Picard, D., ed) , pp. 167-189, Oxford University Press, Oxford
32. Pazin, M. J., Kamakaka, R. T., and Kadonaga, J. T. (1994) Science 266, 2007-2011[Medline] [Order article via Infotrieve]
33. Bulger, M., and Kadonaga, J. T. (1994) Methods Mol. Genet. 5, 241-262
34. Hebbes, T. R., Thorne, A. W., and Crane-Robinson, C. (1988) EMBO J. 7, 1395-1402[Abstract]
35. Ito, T., Levenstein, M. E., Fyodorov, D. V., Kutach, A. K., Kobayashi, R., and Kadonaga, J. T. (1999) Genes Dev. 13, 1529-1539[Abstract/Free Full Text]
36. Ueda, H., Nakajima, H., Hori, Y., Fujita, T., Nishimura, M., Goto, T., and Okuhara, M. (1994) J. Antibiot. (Tokyo) 47, 301-310[Medline] [Order article via Infotrieve]
37. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. (1998) Exp. Cell Res. 241, 126-133[CrossRef][Medline] [Order article via Infotrieve]
38. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. (1990) J. Biol. Chem. 265, 17174-17179[Abstract/Free Full Text]
39. Yoshida, M., Horinouchi, S., and Beppu, T. (1995) Bioessays 17, 423-430[Medline] [Order article via Infotrieve]
40. Pazin, M. J., and Kadonaga, J. T. (1998) in Chromatin: A Practical Approach (Gould, H., ed) , pp. 173-194, Oxford University Press, Oxford
41. Jiang, W., Nordeen, S. K., and Kadonaga, J. T. (2000) J. Biol. Chem. 275, 39819-39822[Abstract/Free Full Text]
42. Robinson, K. M., and Kadonaga, J. T. (1998) Biochim. Biophys. Acta 1378, M1-M6[CrossRef][Medline] [Order article via Infotrieve]
43. Hawley, D. K., and Roeder, R. G. (1985) J. Biol. Chem. 260, 8163-8172[Abstract/Free Full Text]
44. Hawley, D. K., and Roeder, R. G. (1987) J. Biol. Chem. 262, 3452-3461[Abstract/Free Full Text]
45. Kadonaga, J. T. (1990) J. Biol. Chem. 265, 2624-2631[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.